

RESEARCH ARTICLE

# Effects of hyperoxia on $^{18}\text{F}$ -fluoromisonidazole brain uptake and tissue oxygen tension following middle cerebral artery occlusion in rodents: Pilot studies

Tim D. Fryer<sup>1</sup>✉, Sohail Ejaz<sup>2</sup>✉, Ulf Jensen-Kondering<sup>1,2,3</sup>, David J. Williamson<sup>1</sup>, Sergey Sitnikov<sup>2</sup>, Stephen J. Sawiak<sup>1</sup>, Franklin I. Aigbirhio<sup>1</sup>, Young T. Hong<sup>1</sup>, Jean-Claude Baron<sup>2,4\*</sup>

**1** Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom, **2** Stroke Research Group, Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom, **3** Department of Radiology and Neuroradiology, University Medical Center Schleswig-Holstein, Kiel, Germany, **4** Department of Neurology, Hôpital Sainte-Anne Hospital, Université Paris Descartes, INSERM U894, Paris, France

✉ These authors contributed equally to this work.

\* [jean-claude.baron@inserm.fr](mailto:jean-claude.baron@inserm.fr)



## OPEN ACCESS

**Citation:** Fryer TD, Ejaz S, Jensen-Kondering U, Williamson DJ, Sitnikov S, Sawiak SJ, et al. (2017) Effects of hyperoxia on  $^{18}\text{F}$ -fluoromisonidazole brain uptake and tissue oxygen tension following middle cerebral artery occlusion in rodents: Pilot studies. PLoS ONE 12(11): e0187087. <https://doi.org/10.1371/journal.pone.0187087>

**Editor:** Johannes Boltze, Fraunhofer Research Institution of Marine Biotechnology, GERMANY

**Received:** February 25, 2017

**Accepted:** October 15, 2017

**Published:** November 1, 2017

**Copyright:** © 2017 Fryer et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** Data has been deposited in the Open Science Framework. The accession details are: [10.17605/OSF.IO/R958C](https://doi.org/10.17605/OSF.IO/R958C); ARK [c7605/osf.io/r958c](https://doi.org/10.5281/zenodo.1000000).

**Funding:** European Union Grant (<https://europa.eu>) EUSTROKE Health-F2-2008-2022131 provided funding for experiments, consumables, and salaries for S. Ejaz and S. Sitnikov. Medical Research Council ([www.mrc.ac.uk](http://www.mrc.ac.uk)) collaborative grant (G0600986) provided funding for DJ

## Abstract

### Purpose

Mapping brain hypoxia is a major goal for stroke diagnosis, pathophysiology and treatment monitoring.  $^{18}\text{F}$ -fluoromisonidazole (FMISO) positron emission tomography (PET) is the gold standard hypoxia imaging method. Normobaric hyperoxia (NBO) is a promising therapy in acute stroke. In this pilot study, we tested the straightforward hypothesis that NBO would markedly reduce FMISO uptake in ischemic brain in Wistar and spontaneously hypertensive rats (SHRs), two rat strains with distinct vulnerability to brain ischemia, mimicking clinical heterogeneity.

### Methods

Thirteen adult male rats were randomized to distal middle cerebral artery occlusion under either 30%  $\text{O}_2$  or 100%  $\text{O}_2$ . FMISO was administered intravenously and PET data acquired dynamically for 3hrs, after which magnetic resonance imaging (MRI) and tetrazolium chloride (TTC) staining were carried out to map the ischemic lesion. Both FMISO tissue uptake at 2-3hrs and FMISO kinetic rate constants, determined based on previously published kinetic modelling, were obtained for the hypoxic area. In a separate group ( $n = 9$ ), tissue oxygen partial pressure ( $P_{\text{tO}_2}$ ) was measured in the ischemic tissue during both control and NBO conditions.

### Results

As expected, the FMISO PET, MRI and TTC lesion volumes were much larger in SHRs than Wistar rats in both the control and NBO conditions. NBO did not appear to substantially

Williamson salary, and Deutsche Forschungsgemeinschaft ([www.dfg.de](http://www.dfg.de)): grant Je 598/1-1 provided funding for Ulf Jensen-Kondering fellowship. We acknowledge the financial support by the state of Schleswig-Holstein within the funding programme "Open Access Publikationsfonds".

**Competing interests:** The authors have declared that no competing interests exist.

reduce FMISO lesion size, nor affect the FMISO kinetic rate constants in either strain. Likewise, MRI and TTC lesion volumes were unaffected. The parallel study showed the expected increases in ischemic cortex  $P_tO_2$  under NBO, although these were small in some SHRs with very low baseline  $P_tO_2$ .

## Conclusions

Despite small samples, the apparent lack of marked effects of NBO on FMISO uptake suggests that in permanent ischemia the cellular mechanisms underlying FMISO trapping in hypoxic cells may be disjointed from  $P_tO_2$ . Better understanding of FMISO trapping processes will be important for future applications of FMISO imaging.

## Introduction

Ischemic stroke is characterized by focal severe brain hypoxia. In turn, tissue hypoxia triggers the cellular and molecular events that lead to infarction of the 'ischemic penumbra' unless perfusion—and hence oxygen delivery—is rapidly restored [1–4]. Accordingly, mapping brain hypoxia is a major goal for stroke diagnosis but also to investigate stroke pathophysiology and to monitor the effects of therapeutic interventions.  $^{18}F$ -fluoro-misonidazole (FMISO) positron emission tomography (PET) is the gold standard *in vivo* hypoxia imaging method [5] and has been extensively used for stroke research in the last two decades both in rodents [6–14] and acute/subacute stroke patients [15–24]. Following IV bolus administration, plasma FMISO passively diffuses into tissues (including the brain) and washes out over time from normoxic tissues where no retention process occurs; however, in severely hypoxic tissues, FMISO is reduced to a free radical form by reductases active only in viable cells, and the reduced form is irreversibly trapped by covalent binding to intracellular macromolecules (probably large, complex proteins or DNA) according to an incompletely understood mechanism [5]. In other words, the uptake of FMISO and other misonidazole derivatives depends on the presence of both severe tissue hypoxia and cell viability. Importantly, FMISO retention in various tissues has been shown to be highly sensitive to tissue oxygen tension in a non-linear way, mildly increasing with moderate degrees of hypoxia and markedly so at severe hypoxia [25] [26]. With respect to the brain, it is also highly sensitive to perfusion, and hence oxygen delivery, in rodent models of cerebral ischemia [14, 27, 28] as well as in human stroke [15].

Consistent with these notions, rodent studies [10] have documented that while marked tracer retention occurs in hypoxic tissue when FMISO is administered early after permanent middle cerebral artery occlusion (MCAo), no tracer retention occurs if it is administered after release of the occlusion—interpreted as due to disappearance of hypoxia after reperfusion—, or 48hrs after permanent occlusion—as FMISO uptake can only occur in viable cells.

Normobaric hyperoxia (NBO, to be referred to as 'hyperoxia' in what follows) has been shown to improve tissue oxygenation in acute stroke. Hyperoxia indeed increases tissue oxygen partial pressure ( $P_tO_2$ ) in the setting of acute MCAo in rodents, and reduces infarct size when administered early after temporary MCAo (see [29–31] for review).

In the present pilot study, we carried out a series of experiments to test, for the first time to our knowledge, the effects of normobaric hyperoxia on FMISO brain uptake and pharmacokinetics in a rodent MCAo model. Given that FMISO gets irreversibly trapped in hypoxic but viable tissue [5], we predicted that hyperoxia started simultaneously with FMISO administration would markedly reduce FMISO brain uptake. To test this hypothesis, we assessed not only brain tracer retention at the standard 2–3hrs post-administration time, but also FMISO kinetic

rate constants, specifically the irreversible trapping constant thought to reflect tissue hypoxia, by dynamically acquiring FMISO brain data since administration time and applying our previously reported quantitative kinetic model [32]. In addition, to assess the effects of hyperoxia on FMISO uptake in distinct tissue situations, we used both Wistar rats and their spontaneously hypertensive counterparts (SHRs), whose tissue vulnerability to focal cerebral ischemia, namely rate of demise of the severely hypoxic but viable tissue (i.e., the penumbra) [33–35] and final infarct volume [33, 36–40], widely differ as a result of underlying differences in functionality and structure of the pial vascular tree [39, 41–45], in turn mimicking clinical heterogeneity. In parallel to testing the effects of hyperoxia on FMISO uptake, and to inform the findings thereof, we also assessed its effects on tissue oxygen tension in both ischemic and non-ischemic cortex in a different group of animals. Given the pilot nature of this study and the straightforward hypothesis based on indirect but strong evidence, only small subject samples were used throughout, amenable to descriptive statistics only.

## Materials and methods

### Overview

All procedures were in accordance with the ethical standards of the institution at which the studies were conducted. The study was approved by the University of Cambridge Ethical Review Panel. In accordance with the legislation of UK Animals Scientific Procedures Act 1986, the Ethical Review Board required that the study be designed to keep the number of animals used to a minimum, yet sufficient to obtain meaningful results. All subjects that participated in the study will be reported below.

The main aim of our study was to assess the effects of hyperoxia, as compared to the control condition, on FMISO trapping in the affected hemisphere. Secondary objectives were to assess the effects of hyperoxia on i) FMISO kinetic constants, determined using kinetic modelling; and ii) MR and TTC lesion volume, obtained after completion of the FMISO PET study, around 3hrs after MCAo. Based on the literature, we did not expect major effects of hyperoxia on the MR and TTC lesion volumes after permanent MCAo of >3hrs duration [31]. As already mentioned, we also carried out a parallel study on the effects of hyperoxia on brain tissue  $P_tO_2$  to inform the FMISO findings, expecting a significant improvement in ischemic tissue  $P_tO_2$  based on the literature (see above); these experiments were carried out on different rats from the FMISO study because it was not feasible to scan the subjects while the  $PO_2$  probe was inserted in the brain.

### Anesthesia

Experiments were performed in freely breathing animals. Anesthesia was induced with 4% isoflurane administered via a nose cone in a 0.3 l/min  $O_2$  and 0.7 l/min  $N_2O$  mix and maintained with 2% isoflurane during surgical procedures, as per previously published protocols [31, 46]. Body temperature of the animals was monitored with a rectal probe and maintained at  $37.0 \pm 0.5^\circ C$  using a heated pad throughout all surgical procedures. Blood oxygen saturation and heart beat were continuously monitored using a pulse-oximeter and remained within normal ranges throughout. In the hyperoxia group, rats were switched to pure oxygen (1L/min) within 5mins following MCAo (see below). This hyperoxia regimen is standard for testing the effects of normobaric oxygen therapy in rodents (see [30])

### MCAo

Distal left permanent MCAo was performed as detailed previously [47–49]. In brief, the left common carotid artery (CCA) was isolated through a ventral midline incision on the neck and

a loose ligature of 4–0 silk suture was placed around it. With the rat positioned onto its right flank, a 2.5cm skin incision perpendicular to and bisecting a line between the lateral canthus of the right eye and the external auditory canal was made, and the underlying temporalis muscle excised to reveal the base of the skull. Under direct visualization, the underlying temporalis muscle was excised and craniectomy was performed under saline irrigation to expose the left MCA through a 2-mm burr hole drilled 2 to 3 mm rostral to the fusion of the zygomatic arch with the squamosal bone. The dura was retracted to visualize the MCA at a position where it crosses the inferior cerebral vein, which lies within the rhinal fissure. A micro-aneurysm clip (#1 Sundt AVM, Codman, Raynham, USA) was placed on the MCA proximal to the point where it crosses the inferior cerebral vein in the rhinal fissure, and then the left CCA was permanently ligated. To avoid additional procedural complications that may impact tissue outcome, including blood loss from femoral cannulation, arterial blood pressure was not measured here as it is known to be already significantly elevated ( $>170\text{mmHg}$ ) by 3 months of age in SHR $s$  [50].

## PET

Six Wistar rats and seven SHR $s$  were randomized to undergo MCAo under either control ( $n = 3$  and 4 per strain, respectively) or hyperoxia ( $n = 3$  per strain) conditions. These sample sizes were not based on a power calculation given the absence of literature data on expected effect size (i.e., % reduction in FMISO uptake from hyperoxia). They were considered large enough to test our straightforward hypothesis that hyperoxia would markedly reduce FMISO uptake in ischemic regions (see [Introduction](#)), also taking into consideration the aforementioned ethical requirements.

Immediately after clip placement on the MCA, the animal was positioned in the PET scanner (microPET P4, Concorde Microsystems, Knoxville, USA) with the brain located centrally in the field of view. Under the oxygen condition of the scan (control or hyperoxia), within 5mins of MCAo FMISO ( $77 \pm 9 \text{ MBq}$ ) was administered in the tail vein over 30secs [10], with FMISO PET acquisition starting simultaneously with the injection. Dynamic PET data were acquired for 3 hours. The energy and coincidence windows were 350–650keV and 6nsec, respectively, and the voxel size  $0.5 \times 0.5 \times 0.5 \text{ mm}$ . Venous blood samples were taken at 120, 150 and 180 mins post-injection, and plasma radioactivity concentration measured in a well counter to provide values for least squares scaling of a pre-existing arterial plasma input function [32]. Transmission scanning with a rotating  $^{68}\text{Ge}/^{68}\text{Ga}$  point source was conducted at the end of the FMISO scan, with geometrically-windowed coincidence mode used to provide accurate attenuation information in the presence of the residual FMISO radioactivity.

The list-mode data were binned into sinograms for the following time frames:  $8 \times 15\text{s}$ ,  $6 \times 30\text{s}$ ,  $15 \times 1\text{min}$ ,  $5 \times 2\text{min}$ ,  $30 \times 5\text{min}$ . For each sinogram, an image was reconstructed using the PROMIS 3D filtered backprojection algorithm [51], with a Hann window applied to result in a reconstructed image resolution of 2.3mm full width at half maximum (FWHM). Image reconstruction incorporated corrections for randoms, dead time, normalisation, attenuation, decay and sensitivity.

## MRI

Immediately on completion of PET scanning the animal was transported to the nearby room for magnetic resonance imaging (MRI) (4.7T Bruker BioSpec 47/40 system; Bruker BioSpin, Ettlingen, Germany). Diffusion weighted images (DWI) were acquired using an echo-planar sequence (TR/TE 3000/35ms, 35 directions  $b = 1000\text{s/mm}^2$ , slice thickness 1.5mm, in plane resolution 0.312mm). T2-weighted MRI was then acquired using the following parameters:

TR/TEeff 15078/36ms, ETL 8, NEX 1,  $256 \times 256 \times 128$  FOV  $64.0 \times 64.0 \times 32.0$  mm<sup>3</sup>, isotropic resolution 250  $\mu$ m<sup>3</sup>.

## Histology

Immediately after completion of the MRI, the animal was killed with an overdose of phenobarbital and decapitated. Tetrazolium chloride (TTC) staining was then performed according to the previously described methodology [10]. The brains were isolated and cut into 2mm thick sections, which were incubated in 0.5% TTC bath at room temperature, and then scanned on a flatbed scanner.

## Image analysis

All image analyses were carried out blind to group allocation.

**FMISO SUV images.** For each animal, an FMISO standardised uptake value (SUV) map was created by averaging the images 120–180min post-injection, and multiplying this by the ratio of animal weight (kg) to injected activity (MBq). This SUV map was manually rigidly co-registered to the MR image of the same animal. For comparison of SUV maps, each individual MR image was affine-registered to a MRI brain template of a normal rat, and this transformation was applied to the co-registered SUV map to bring it to template space.

**FMISO hypoxic ROI.** Based on our hypothesis, hyperoxia should reduce the volume with significantly increased FMISO. Accordingly, the analysis followed our previously published methodology [11]. First, a region-of-interest (ROI) was defined on the MR image that encompassed the cerebral hemisphere contralateral to the MCAo, within which the mean and standard deviation (SD) of the voxel SUV values were determined. Under the assumption of normally distributed values, a statistical threshold of  $p < 0.001$  was calculated from mean +  $4.26 \times \text{SD}$ . This threshold was applied to the MCAo hemisphere to delineate the hypoxic volume [11]. The mean SUV within the FMISO hypoxic ROI was also obtained in each rat.

**FMISO kinetic rate constants.** FMISO kinetic rate constants were determined within the FMISO hypoxic and contralateral hemisphere ROIs using our previously published kinetic modelling methodology [32]. To this end, a plasma-input two-compartment irreversible kinetic model was applied to the mean hypoxic volume time-activity curve (TAC) and the corresponding TAC from the contralateral hemisphere ROI [32], resulting in the estimation of two measures of FMISO trapping per region: trapping rate ( $k_3$ ) and influx rate ( $K_i$ ).

**MRI.** DWI images displayed the expected ischemic lesions in all rats (see Results), but the metallic clip for MCAo resulted in significant artefacts. Ischemic lesion volumes were therefore delineated on the T2-weighted MRI by an experimental neuroscientist with experience in stroke imaging (SE) and blinded to subject group, by manually contouring using MRICro ([www.cabiatl.com/mricro/mricro/](http://www.cabiatl.com/mricro/mricro/)) the volume of increased signal across the coronal slices displaying a lesion in the left MCA territory cortex.

**TTC lesion.** Two observers blinded to subject group independently determined the TTC lesion volume from the scanned TTC sections using ImageJ (<https://imagej.nih.gov/ij/>). As the agreement between these observers was high ( $R^2 = 0.944$ ,  $p < 0.001$ ), the average TTC volumes across the two observers was used henceforth.

## MCA cortex $P_tO_2$

The experimental protocol, including methodology for distal microclip MCAo, anesthetic regimen and physiological monitoring, was identical to that used in the PET studies above.  $P_tO_2$  was measured using an  $O_2$  probe (Tissue Oxygenation Monitor, Oxy lab  $pO_2$ , Oxford Optinix, Abingdon, UK) in adult male ~3 months old SHR (n = 5; weight: ~300g) and Wistar rats (n = 4;

weight: ~300g). Based on the literature and our previously published findings [48], we elected to measure  $P_tO_2$  in the barrel field of the primary somatosensory cortex (S1-BF), because it is consistently part of the cortical MCA territory [52, 53] and is among the areas most severely and consistently affected after distal MCAo in SHRs [48]. To this end, under 1.5% continuous isoflurane delivery, the  $O_2$  probe was inserted in the S1-BF under stereotaxic conditions, using coordinates from the Paxinos atlas (bregma -2mm, lateral 6mm, depth 1mm) [54].  $P_tO_2$  was measured first in the right hemisphere starting 30mins after probe insertion to allow for resolution of acute tissue trauma as recommended.  $P_tO_2$  values were then obtained every 10 mins during one 30-min control and hyperoxia cycle, allowing 10mins to elapse between the two conditions for equilibrium. Once these measurements completed, the oxygen probe was removed and left-sided distal MCAo was carried out as described above. The probe was inserted in the S1-BF of the ischemic hemisphere and measurements started 30mins after MCAo. In total, 18 measurements of  $P_tO_2$  were obtained for the ischemic hemisphere, i.e., every 10 mins during three 30-min control and hyperoxia cycles, allowing 10mins to elapse between the two conditions for equilibrium, for an overall 180mins recording. The experimental design is shown in Fig 1. The  $P_tO_2$  values were subsequently averaged to generate a single value for each condition and each hemisphere.

## Statistical analysis

The Anderson-Darling test [55] was used to test for normality in data distributions and differences in data (for paired data). Consequently, FMISO hypoxic lesion, MRI lesion and TTC lesion volumes were compared between-strain within-condition and within-strain between-condition using two-sample, two-tailed unequal variance t-tests. FMISO values (SUV,  $k_3$  and  $K_i$ ) were compared within-strain between-condition using two-sample, two-tailed unequal variance t-tests, with  $k_3$  and  $K_i$  also compared within-strain within-condition between the hypoxic and contralateral ROIs using paired, two-tailed t-tests. Note that the SUV values were not compared between hemispheres given that the hypoxic ROI was defined statistically based on contralateral hemisphere SUV (mean and SD), i.e., by definition the FMISO lesion ROI only encompassed voxels with significantly higher SUV than the mean contralateral hemisphere SUV. Correlations between FMISO hypoxic lesion, MRI lesion and TTC lesion volumes were assessed using the Pearson correlation coefficient.

$P_tO_2$  data were compared within-strain between-condition using paired, two-tailed t-tests, and between-strain for the control condition using a two-sample, two-tailed unequal variance t-test for the contralateral hemisphere and Wilcoxon rank sum for the MCAo cortex given that the SHR MCAo cortex  $P_tO_2$  distribution failed the Anderson-Darling normality test ( $p = 0.008$ ). Differences in  $P_tO_2$  within-strain between-condition satisfied the normality test and hence these difference data were compared between-strain using two-sample, two-tailed unequal variance t-tests. Pooled  $P_tO_2$  data for the MCAo cortex (i.e., by combining SHR and Wistar rats) failed normality ( $p = 0.008$ ) for the difference between conditions and hence were tested between-condition using the Wilcoxon signed rank test.


Given the small samples used in the present study, statistical trends, i.e., two-tailed  $p$  values between 0.10 and 0.05, will be reported as potentially meaningful.

## Results

No animal died before the end of the experiment, and all studied animals are reported below.

Fig 2 shows representative coregistered FMISO SUV, DWI and T2-weighted MRI coronal sections from an SHR and a Wistar rat, illustrating conspicuous FMISO and DWI lesions, somewhat faint T2-weighted lesions, as well as the TTC lesion from approximately the same coronal section.






**Fig 1. Graph showing  $P_tO_2$  data from one subject to illustrate the experimental protocol.** First, following an equilibration period of 30mins after probe insertion (not shown), six  $P_tO_2$  measurements were obtained in the non-ischemic (right) hemisphere (3 control, 3 under hyperoxia), then MCAo and  $PO_2$  probe insertion were carried out on the ischemic (left) hemisphere and  $P_tO_2$  was measured every 10mins (again following a 30-min equilibration period after probe insertion) across three 30min control-hyperoxia cycles (18 measurements in total). Note the rapid equilibration in  $P_tO_2$  after each change of oxygen condition, i.e., within the 10mins between measurements.

<https://doi.org/10.1371/journal.pone.0187087.g001>

## Effects of hyperoxia on FMISO hypoxic ROI volumes

During MCAo, FMISO hypoxic volumes were markedly and significantly larger in SHR than Wistar rats in both the control ( $t = 3.57$ ;  $p = 0.038$ ) and hyperoxia ( $t = 13.34$ ;  $p = 0.006$ ) conditions; Table 1 and Fig 3. As Table 1 shows, the FMISO lesion volumes were not significantly



**Fig 2. Illustrative coregistered FMISO SUV, DWI and T2-weighted MRI images for the same coronal cut in one spontaneously hypertensive rat and one Wistar rat, and approximately matched TTC coronal slice.** These data illustrate the topographic congruence of the ischemic lesions (arrows) among the four imaging modalities. As TTC sections are not amenable to coregistration with PET and MR images due to differences in slice angle and thickness and potential *post-mortem* geometrical distortion, approximately same coronal level TTC sections as for the *in vivo* images are shown for illustrative purposes only.

<https://doi.org/10.1371/journal.pone.0187087.g002>

smaller in the hyperoxia condition as compared to control in either strain, and in SHRs tended in fact to be larger ( $p = 0.08$ ). Fig 4 illustrates these findings in two typical rats per strain.

## Effects of hyperoxia on MRI and TTC lesion volumes

All rats exhibited an acute hyperintense lesion on DWI, but the metallic clip placed onto the MCA consistently induced susceptibility artefacts, which precluded determination of DWI lesion volumes. Accordingly, lesion volumes were determined on the T2-weighted scans. As with the FMISO hypoxic ROI, larger MRI and TTC lesion volumes were present in SHRs as compared to Wistar rats in both control (MRI:  $t = 4.27$ ,  $p = 0.024$ ; TTC:  $t = 2.67$ ,  $p = 0.08$ ) and hyperoxia (MRI:  $t = 2.91$ ,  $p = 0.10$ ; TTC:  $t = 11.68$ ,  $p = 0.001$ ) conditions (Table 1, Fig 3). Within-strain analyses, however, revealed no significant difference between the control and hyperoxia conditions in both SHRs and Wistar rats (Table 1). Across conditions, there were robust ( $R^2 = 0.55$ – $0.74$ ; all  $p < 0.001$ ) correlations among lesion volumes from FMISO PET, MRI and TTC (Fig 5).


**Table 1. Mean ( $\pm$  SD) FMISO PET hypoxic volume and MRI and TTC lesion volumes for both rat strains and oxygen supply conditions, together with corresponding  $t$  and  $p$  values from two-sample, two-tailed, unequal variance  $t$ -tests between control and hyperoxia oxygen conditions.**

| Strain | Modality | Condition | Volume [ $\text{mm}^3$ ] | $t$ (p-value)          |
|--------|----------|-----------|--------------------------|------------------------|
| SHR    | FMISO    | Control   | $207 \pm 110$            | $2.34$ ( $p = 0.08$ )  |
|        |          | Hyperoxia | $349 \pm 44$             |                        |
|        | MRI      | Control   | $91 \pm 38$              | $0.31$ ( $p = 0.78$ )  |
|        |          | Hyperoxia | $103 \pm 59$             |                        |
|        | TTC      | Control   | $136 \pm 87$             | $0.96$ ( $p = 0.41$ )  |
|        |          | Hyperoxia | $179 \pm 22$             |                        |
| Wistar | FMISO    | Control   | $11 \pm 6$               | $-0.35$ ( $p = 0.74$ ) |
|        |          | Hyperoxia | $9 \pm 6$                |                        |
|        | MRI      | Control   | $7 \pm 9$                | $-0.64$ ( $p = 0.57$ ) |
|        |          | Hyperoxia | $3 \pm 5$                |                        |
|        | TTC      | Control   | $18 \pm 15$              | $-0.66$ ( $p = 0.54$ ) |
|        |          | Hyperoxia | $11 \pm 13$              |                        |

FMISO,  $^{18}\text{F}$ -fluoro-misonidazole; PET, positron emission tomography; MRI, magnetic resonance imaging; TTC, tetrazolium chloride; SHR, spontaneously hypertensive rat

<https://doi.org/10.1371/journal.pone.0187087.t001>





**Fig 3. Individual and mean FMISO hypoxia, T2-weighted MRI and TTC lesion volumes for SHR and Wistar rats under control and hyperoxia conditions.** Horizontal lines denote the mean of each group. FMISO, MRI and TTC lesion volumes were significantly larger in SHR than Wistar rats in both conditions (see Results section for further details), but there was no significant effect of hyperoxia in either strain. Sample sizes are  $n = 3-4$  per group.


<https://doi.org/10.1371/journal.pone.0187087.g003>

### Effects of hyperoxia on SUV within the FMISO lesion ROI

Fig 6 shows individual and mean SUV values across both conditions and strains. FMISO lesion ROI SUV did not differ between the two conditions, either in SHR (mean  $\pm$  SD:  $1.17 \pm 0.20$  g/ml control vs  $1.33 \pm 0.14$  g/ml hyperoxia;  $t = 1.22$ ,  $p = 0.28$ ) or in Wistar rats ( $1.24 \pm 0.15$  vs  $1.04 \pm 0.16$  g/ml;  $t = -1.62$ ,  $p = 0.18$ ). Also, there was no effect of hyperoxia on contralateral hemisphere SUV values in either SHR ( $0.62 \pm 0.06$  vs  $0.67 \pm 0.08$  g/ml;  $t = 0.94$ ,  $p = 0.40$ ) or Wistar rats ( $0.65 \pm 0.03$  vs  $0.64 \pm 0.06$  g/ml;  $t = -0.13$ ,  $p = 0.91$ ).

### Effects of hyperoxia on FMISO kinetic rate constants within the FMISO lesion ROI

Fig 7 shows typical examples of the compartmental model fits to the FMISO time-activity curves (TACs) for the FMISO hypoxic lesion ROI and contralateral ROI of both strains under the control and hyperoxia conditions.




**Fig 4. Representative FMISO SUV images overlaid on the same coronal slice of the co-registered MRI template for representative SHR (top row) and Wistar (bottom row) rats scanned under either the control (left column) or hyperoxia (right column) conditions.** The pseudocolor scale on the right represents SUV units (see text for details). This illustrates the much smaller FMISO lesion induced by distal MCA occlusion in Wistar rats than SHRs, and the lack of clear effect of hyperoxia on FMISO brain uptake in either strain (see Results for further details).

<https://doi.org/10.1371/journal.pone.0187087.g004>

As also depicted in Fig 6, FMISO influx rate ( $K_i$ ) was significantly higher in the hypoxic lesion compared to the contralateral ROI for SHR rats under both conditions (control mean  $\pm$  SD:  $0.0045 \pm 0.0005$  vs  $0.0010 \pm 0.0003$  ml/min/ml;  $t = 20.41$ ,  $p = 0.031$ ; hyperoxia:  $0.0047 \pm 0.0011$  vs  $0.0011 \pm 0.0003$  ml/min/ml;  $t = 7.37$ ,  $p = 0.018$ ) and for Wistar rats under the control condition ( $0.0038 \pm 0.0011$  vs  $0.0007 \pm 0.0003$  ml/min/ml;  $t = 6.44$ ,  $p = 0.023$ ), with a near significant result for Wistar rats under hyperoxia ( $0.0027 \pm 0.0006$  vs  $0.0009 \pm 0.0002$  ml/min/ml;  $t = 4.19$ ,  $p = 0.052$ ). The FMISO trapping rate ( $k_3$ ) was also significantly higher in the FMISO lesion relative to its mirror ROI in SHRs under hyperoxia ( $0.0170 \pm 0.0037$  vs  $0.0027 \pm 0.0003$  min<sup>-1</sup>;  $t = 7.14$ ,  $p = 0.019$ ) and Wistar rats in the control condition ( $0.0085 \pm 0.0032$  vs  $0.0014 \pm 0.0005$  min<sup>-1</sup>;  $t = 4.60$ ,  $p = 0.044$ ), with similar trends in SHRs in the control condition ( $0.0157 \pm 0.0024$  vs  $0.0027 \pm 0.0004$  min<sup>-1</sup>;  $t = 6.56$ ,  $p = 0.10$ ) and Wistar rats under hyperoxia ( $0.0071 \pm 0.0035$  vs  $0.0024 \pm 0.0007$  min<sup>-1</sup>;  $t = 2.09$ ,  $p = 0.17$ ). However, as for SUV, hypoxic lesion  $K_i$  and  $k_3$  did not significantly differ between control and hyperoxia in either strain ( $|t| \leq 1.46$ ,  $p \geq 0.24$  in all cases).


## Effects of hyperoxia on cortical $P_tO_2$

Fig 8 illustrates the  $P_tO_2$  values in the non-ischemic and ischemic cortex in both strains and both conditions. In the non-ischemic cortex,  $P_tO_2$  was significantly lower in SHRs than Wistar



**Fig 5. Relationships between FMISO hypoxic lesion volume, MRI lesion volume and TTC lesion volume.** Each plot uses data from both SHR and Wistar rats under both the control and hyperoxia conditions ( $n = 13$ ). All Pearson correlations are statistically significant ( $p < 0.001$ ;  $R^2$  values shown next to each scatterplot).

<https://doi.org/10.1371/journal.pone.0187087.g005>




**Fig 6. Individual and mean FMISO SUV (left column), influx rate ( $K_1$ ; middle) and trapping rate ( $k_3$ ; right) in the FMISO lesion ROI and contralateral ROI for SHR (top row) and Wistar (bottom row) rats under the control and hyperoxia conditions.** Horizontal bars denote mean values. The  $K_1$  and  $k_3$  values were higher (significantly or with a strong trend) in the affected ('lesion') as compared to the non-ischemic (contralateral) hemisphere in both strains and both conditions (see [Results](#) section for details). However, there was no significant effect of hyperoxia on SUV,  $K_1$  or  $k_3$  in either strain.

<https://doi.org/10.1371/journal.pone.0187087.g006>

rats in the control condition (mean  $\pm$  SD:  $24.3 \pm 8.6$  vs  $45.9 \pm 12.2$  mmHg;  $t = -3.00$ ,  $p = 0.030$ ), with significant increases in  $P_tO_2$  during hyperoxia found for both the SHRs (mean increase:  $15.9$  mmHg;  $t = 3.39$ ,  $p = 0.028$ ) and Wistar rats (mean increase:  $32.1$  mmHg;  $t = 14.30$ ,  $p = 0.001$ ). The increase in  $P_tO_2$  for Wistar rats was significantly greater than for SHRs ( $t = 3.11$ ,  $p = 0.021$ ). Increases in  $P_tO_2$  had a positive correlation trend with initial  $P_tO_2$  for Wistar rats ( $R^2 = 0.84$ ,  $p = 0.08$ )—i.e., the higher the baseline  $P_tO_2$ , the larger the increase—, but not for SHRs ( $R^2 = 0.02$ ,  $p = 0.84$ ).

Ischemic cortex  $P_tO_2$  was also significantly lower in SHRs than in Wistar rats in the control condition (median  $0.6$  vs  $16.8$  mmHg;  $p = 0.032$ ; Wilcoxon rank sum). As shown in [Fig 8](#), ischemic cortex  $P_tO_2$  increased during hyperoxia in all 9 rats although to highly variable degrees. The increase in  $P_tO_2$  was statistically significant when pooling the two strains ( $p = 0.004$ ;  $n = 9$ ; Wilcoxon signed rank). Due to the small samples for each strain, increases in ischemic cortex  $P_tO_2$  only showed a weak trend when tested separately for SHRs (mean increase:  $6.2$  mmHg;  $t = 1.72$ ,  $p = 0.16$ ;  $n = 5$ ) and Wistar rats (mean increase:  $26.4$  mmHg,  $t = 1.95$ ,  $p = 0.15$ ;  $n = 4$ ). The increases in  $P_tO_2$  for SHRs and Wistar rats were not significantly different ( $t = 1.44$ ,  $p = 0.25$ ).



**Fig 7. Representative FMISO time-activity curves for the FMISO hypoxic lesion ROI and contralateral ROI for the 3-hr PET scan, together with compartmental fits for SHR (top row) and Wistar (bottom row) rats under the control (left column) and hyperoxia conditions (right column).**

<https://doi.org/10.1371/journal.pone.0187087.g007>


Increases in  $P_tO_2$  were found to positively correlate with initial  $P_tO_2$  for SHRs ( $R^2 = 0.97$ ,  $p = 0.003$ ), but not for Wistar rats ( $R^2 = 0.15$ ,  $p = 0.62$ ).

## Discussion

This pilot study is the first to assess the effects of hyperoxia on FMISO uptake during cerebral ischemia. Our experiments were designed to test a straightforward hypothesis, namely that hyperoxia initiated within minutes of onset of focal cerebral ischemia would markedly reduce FMISO uptake in the occluded MCA territory. Accordingly, only small samples and descriptive statistics were thought adequate to demonstrate this. Contrary to our expectations, however, neither the FMISO hypoxic lesion volume nor the FMISO SUVs and kinetic rate constants within this region were clearly affected in either rat strain. This included  $k_3$  which represents unidirectional FMISO cell trapping assumed to directly reflect tissue hypoxia [26, 32].

To test our hypothesis, we elected to use a 3hr MCA occlusion paradigm. This was necessary because 3hrs of tracer uptake are recommended to obtain reliable data from FMISO studies, due to its slow tissue kinetics and trapping in hypoxic tissue [5] (see Fig 7 for an illustration). In addition, with any radiotracer study steady-state physiological conditions are required throughout data acquisition, precluding the use of temporary MCAo with reperfusion before the 3hr time-point. Unfortunately, as of today there is no alternative brain-penetrant *in vivo* hypoxia tracer with faster kinetics or reversible trapping [5, 56].

Our hypothesis was underpinned by earlier reports that FMISO trapping strongly depends on the degree of hypoxia, be it for the liver [57] or tumors [26]. How can these unexpected results be explained? First, small samples could have caused Type 2 error, i.e., lack of statistical



**Fig 8. Individual cortical  $PO_2$  ( $P_tO_2$ ) measured in the MCA territory in the non-ischemic hemisphere (left) and ischemic hemisphere (right) under the control and hyperoxia conditions in SHR (top) and Wistar rats (bottom;  $n = 5$  and  $4$ , respectively).** Each line joins  $P_tO_2$  values obtained under both conditions for a single rat; different colors are used for ease of illustration. The inset on the top right zooms on the four SHRs with lowest baseline  $P_tO_2$  values, which are difficult to discriminate on the main graph due to the common scale used across graphs. This figure shows lower  $P_tO_2$  under ischemic vs control condition in both strains, and increases in  $P_tO_2$  under hyperoxia in all 9 rats (although of very small amplitude in one SHR), which was highly statistically significant with pooled data. However, due to small samples and highly variable  $P_tO_2$  increases, only trends were found when strains were assessed separately. The increase in  $P_tO_2$  by hyperoxia was not significantly different between the two strains in the ischemic cortex, although was significantly higher for Wistar rats in the contralateral hemisphere. Statistical tests also showed significantly higher  $P_tO_2$  in the control condition in Wistar rats as compared to SHRs in both hemispheres (see Results for further details).

<https://doi.org/10.1371/journal.pone.0187087.g008>

significance despite the presence of a difference. However—again contrary to our expectations—no discernible or consistent effect on FMISO lesion volume, SUV or kinetic rate constants was observed in either strain, and, if anything, a trend for *enlarged* FMISO lesion was present in SHRs (Table 1).

Second, the hyperoxia regimen implemented here was perhaps insufficient to substantially improve ischemic tissue oxygenation and in turn reduce FMISO uptake. However, it increased arterial  $PO_2$  4-fold (from mean 121.5 mmHg to mean 478.5 mmHg; corresponding  $S_aO_2$  values: 98.7% and 100%, respectively) [31]. Despite such marked  $P_aO_2$  rises, normobaric hyperoxia is known not to result in major increases in arterial oxygen content, and hence in oxygen delivery to tissues. However, hyperbaric hyperoxia is a cumbersome procedure that would not be compatible with PET and MRI scanning. Consistent with the literature [46, 58–60], the NBO regimen applied here did however result in significant increases in ischemic cortex  $P_tO_2$  across

the two strains (i.e., pooled data)—although within strain these increases did not quite reach statistical significance, probably due to small samples and variable changes.

Third,  $P_tO_2$  was measured in a small volume whereas we assessed FMISO uptake throughout the brain, which might account for our results. However, we purposely elected the S1-BF area for  $P_tO_2$  assessments because this cortical region is well within the MCA territory [52, 53], and was previously shown to exhibit very low perfusion values after distal MCAo in SHR [48]. Secondly, we performed a *post-hoc* analysis of FMISO SUV within the S1-BF ROI, as per our previously published methodology [31, 61]. To this end, the Paxinos stereotaxic atlas [54] was co-registered onto MRI brain templates from normal adult SHR and Wistar rats, and the S1-BF ROI from this atlas was projected onto co-registered FMISO PET images. As for the FMISO lesion ROI, these results showed no significant effect of hyperoxia on SUV values (data not shown).

Fourth, ischemic cortex  $P_tO_2$  was very low in some SHRs at baseline, and increased only slightly in some rats, which could in part explain the negative findings in SHRs. Liu et al [60] have reported that in rodent MCAo, NBO resulted in marked increases in  $P_tO_2$  in the penumbra but not in the ischemic 'core', which exhibited very low baseline  $P_tO_2$  values similar to that found in some of our SHRs. However, larger increases in  $P_tO_2$  might have occurred in other cortical areas that we did not assess, and although it would have been of interest to assess  $P_tO_2$  in additional brain areas, this was not feasible given the available facilities. Furthermore, interpretation of the Liu et al finding [60] is not straightforward, as in severely ischemic conditions the oxygen extraction fraction is near-maximal [4], so that increasing oxygen delivery to viable tissue would result in increased oxygen use and therefore not necessarily in marked increases in  $P_tO_2$ , despite overall improved oxygenation. One might also argue that such very low  $P_tO_2$  values indicate that the affected tissue is already irreversibly damaged (i.e., the 'core'), and hence that NBO might not have enhanced  $P_tO_2$  in such conditions, resulting in unchanged FMISO lesion volumes. However, even though SHRs have worse hypoperfusion [33–35] and hypoxia after MCAo than Wistar rats (as shown here), they do have an extensive penumbra initially [33–35, 62], and early interventions such as reperfusion and hyperoxia but also drugs do salvage the penumbra and reduce final infarct in SHRs [31, 47, 63–66], indicating that NBO should have affected FMISO uptake and retention, albeit probably less so than in Wistar rats.

Fifth, and linked with the point just discussed, although the  $P_tO_2$  measurements purposely overlapped most of the FMISO tissue uptake period, allowing their comparison, they began 30mins after MCAo in the ischemic cortex, again to comply with technical constraints (see [Methods](#)). We therefore cannot exclude that larger initial increases in  $P_tO_2$  (i.e., the first 30 minutes) occurred, and then reduced over time, explaining the lack of changes in the 2–3hrs SUV images used to determine the FMISO lesion volumes. However, our  $P_tO_2$  data showed steady increases after hyperoxia until the end of measurement (see [Fig 1](#)). Furthermore, because of its trapping process, FMISO SUV measured 2–3hrs after tracer injection reflects uptake from all time points, including early ones [5].

Sixth, again linked with the above two points, FMISO trapping might be sensitive to hyperoxia only for a short duration, while cells are still fully viable. However, in this event inspection of the TACs should have revealed changes in their initial phase, which were not observed ([Fig 7](#)), and the kinetic modelling results would also have been affected, including poor fits, which again was not seen.

Seventh, FMISO trapping in hypoxic brain tissue might occur as an all-or-nothing phenomenon, below a  $P_tO_2$  higher than that achieved during hyperoxia; however, the previously published relationships between  $P_tO_2$  and FMISO trapping in other organs [26, 57], although strongly non-linear, do not support this idea.



Overall, therefore, although the use of small samples precludes us from reaching any definitive conclusion, there are no clear method-related explanations for our unexpected findings. Importantly, however, they are in fact consistent with two previous studies using other nitroimidazole derivatives in rodent stroke models, and *ex vivo* instead of *in vivo* imaging here. One 2-hr MCAo study in mice reported no effect of NBO on hypoxic volumes determined *ex vivo* 135min after IV administration of non-radioactive EF-5 [67]; a finding not addressed by the authors. In another 2-hr MCAo study performed in Sprague-Dawley rats, NBO administered together with perfluorocarbons early after MCAo resulted in major (2 to 4-fold) reductions in core volume (assessed using Silver staining) but only minor (15–20%) reductions in hypoxia volume, assessed using the *ex vivo* pimonidazole method 8 or 24hr later [68]. These earlier findings are entirely consistent with our observations. Note that in our study FMISO lesion volumes also slightly decreased under NBO in Wistar rats by ~15% on average (Table 1), although this showed not even a trend for significance due to major individual values overlap (Fig 3).

Thus, an alternative, biochemical hypothesis to explain our negative results is worth considering. For instance, despite higher  $P_tO_2$ , actual intracellular oxygenation might rapidly decline after a brief initial improvement, due for instance to mitochondrial dysfunction. In favor of this hypothesis, in their report [67] Sun et al found that, 2-hr after start of MCAo, hyperoxia did not significantly affect tissue levels and expression of HIF-1 $\alpha$ —a cell protein increased by hypoxia. Effectively, it is known that rather than tissue  $P_tO_2$ , what nitroimidazole derivatives assess is some downstream cell process triggered by hypoxia and involving irreversible trapping into cell organelles, whose intimate mechanisms are still unclear [5, 69].

In our study, practical factors (see Methods) precluded measuring  $P_tO_2$  in the same rats that underwent FMISO scans. Assuming these technical issues can be resolved, future FMISO studies should directly compare tracer uptake to brain  $P_tO_2$ . For similar reasons, laser Doppler blood flow measurements to confirm effective ischemia following MCAo could not be carried out in conjunction with PET. However, we have previously published perfusion values after distal MCAo in SHR [48], and in addition, all rats in our study had both FMISO and DWI lesions, indicating effective ischemia. To further clarify the relationships between brain  $P_tO_2$  and FMISO uptake after MCAo in animal stroke models in both control and NBO conditions, future studies should not only involve at least twice larger samples, but could also map other MR-based tissue markers of ischemia severity, such as ADC and possibly lactate and NAA. These would need to be monitored simultaneously with FMISO PET, which is now feasible using PET/MR hybrid scanners [70]. Likewise, FMISO PET acquisition could run in parallel with pimonidazole brain uptake, allowing hypoxia mapping directly in brain slices collected at the end of PET acquisition; this could also be combined with HIF-1 $\alpha$  immunoblotting. Finally, and more generally, biochemistry studies addressing the intricate cellular mechanisms of FMISO trapping in conditions of focal ischemia are warranted.

Turning to the lack of effect of hyperoxia on MRI and TTC lesion volumes in either rat strain, this was not unexpected as it is consistent with the literature mostly indicating no or only marginal reductions in infarct volumes with MCAo durations >2hrs [71–75], including in SHR [76], in contrast with shorter MCAo [46, 59, 77–83], again including SHR [31]. Although rodent and clinical studies have documented effective ‘freezing’ of DWI lesion growth during hyperoxia [74, 84, 85], this benefit is lost if reperfusion does not occur soon enough, even despite improved tissue oxygenation. This dependence on early reperfusion is akin that of the penumbra, whereby at some point in time—determined by the severity of hypoperfusion—the penumbra tilts towards irreversible damage [4, 86]. However, why FMISO uptake was not affected by hyperoxia is a different matter, and remains unexplained.

In Wistar rats, MCAo resulted in ~3-fold reductions in ischemic cortex  $P_tO_2$  relative to control conditions. Though we could not identify previous similar studies in this strain, this low  $P_tO_2$  is broadly consistent with an extensive literature in other rat strains [58–60, 73], mice [46] and non-human primates [87, 88] as well as in man [89–91]. Quite strikingly, ischemic cortex  $P_tO_2$  was considerably lower in SHR rats than in Wistar rats. We are not aware of previous studies of  $P_tO_2$  in SHR rats during MCAo. This probably reflects this strain's poor leptomeningeal collaterals and impaired cerebrovascular autoregulation, resulting from increased vessel stiffness, thicker wall and reduced lumen [39, 41–45].

Normobaric hyperoxia increased ischemic cortex  $P_tO_2$  ~2-fold in both strains, consistent with previous literature in Sprague Dawley rats [58, 59] and mice [46]. Thus, the marked (~4-fold) increase in arterial  $PO_2$  achieved during hyperoxia did improve ischemic tissue oxygenation. Given that persistent tissue hypoxia is the main trigger of the ischemic cascade that eventually leads to irreversible cell death and tissue necrosis [1, 2], these effects of hyperoxia are promising and should foster clinical trials. However, the present study again documents that hyperoxia does not reduce ischemic lesion size if arterial occlusion persists beyond a certain time point.

Another interesting finding from the present study is that baseline cortical  $P_tO_2$  was much lower in SHR rats as compared to Wistar rats. We are not aware of any previous study of cortical  $P_tO_2$  in SHR rats. Only Weaver et al [92] reported brain  $P_tO_2$  values in adult SHR rats, but this was for white matter only, and no data from Wistar rats were presented as control. Interestingly, one study found reduced global cerebral blood flow in stroke-prone SHR rats even before the development of infarcts or behavioral impairment [93], thought to indicate the presence of tissue hypoxia. This chronic relative brain hypoxia in SHR rats likely relates to the above-mentioned poorer cerebrovascular tree, and likely underlies the much larger effects of MCAo in SHR rats discussed above. By extension, chronic brain hypoxia might contribute to the larger ischemic lesions seen in hypertensive patients in the clinical setting [94]. In this respect, it would be interesting to test whether chronic anti-hypertensive therapy increases baseline brain  $P_tO_2$  in SHR rats.

*In conclusion*, the unexpected apparent lack of marked effect of hyperoxia on FMISO brain uptake and kinetic rate constants despite partially improved tissue oxygenation observed in this pilot study suggests that in circumstances such as prolonged ischemia, the cellular mechanisms underlying FMISO trapping in hypoxic tissue may be disjointed from interstitial oxygen pressure. A better understanding of FMISO trapping processes will be important for further applications of FMISO PET imaging.

## Acknowledgments

The authors are grateful to S. Tulasi Marrapu for support with data analysis.

## Author Contributions

**Conceptualization:** Tim D. Fryer, Sohail Ejaz, Ulf Jensen-Kondering, Jean-Claude Baron.

**Data curation:** Ulf Jensen-Kondering.

**Formal analysis:** Tim D. Fryer, Young T. Hong.

**Funding acquisition:** Jean-Claude Baron.

**Investigation:** Tim D. Fryer, Sohail Ejaz, Ulf Jensen-Kondering, David J. Williamson, Sergey Sitnikov, Stephen J. Sawiak, Young T. Hong.

**Methodology:** Tim D. Fryer, David J. Williamson, Sergey Sitnikov, Stephen J. Sawiak, Franklin I. Aigbirhio, Young T. Hong.

**Project administration:** Jean-Claude Baron.

**Resources:** Jean-Claude Baron.

**Supervision:** Jean-Claude Baron.

**Writing – original draft:** Tim D. Fryer, Jean-Claude Baron.

**Writing – review & editing:** Tim D. Fryer, Jean-Claude Baron.

## References

1. Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. *Neuron*. 2010; 67(2):181–98. <https://doi.org/10.1016/j.neuron.2010.07.002> PMID: 20670828.
2. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. *Trends Neurosci*. 1999; 22(9):391–7. PMID: 10441299.
3. Astrup J, Siesjö BK, Symon L. Thresholds in cerebral ischemia—the ischemic penumbra. *Stroke*. 1981; 12(6):723–5. PMID: 6272455.
4. Baron JC. Mapping the ischaemic penumbra with PET: implications for acute stroke treatment. *Cerebrovasc Dis*. 1999; 9(4):193–201. PMID: 10393405.
5. Takasawa M, Moustafa RR, Baron JC. Applications of nitroimidazole in vivo hypoxia imaging in ischemic stroke. *Stroke*. 2008; 39(5):1629–37. <https://doi.org/10.1161/STROKEAHA.107.485938> PMID: 18369176.
6. Saita K, Chen M, Spratt NJ, Porritt MJ, Liberatore GT, Read SJ, et al. Imaging the ischemic penumbra with 18F-fluoromisonidazole in a rat model of ischemic stroke. *Stroke*. 2004; 35(4):975–80. <https://doi.org/10.1161/01.STR.0000121647.01941.ba> PMID: 15017016.
7. Spratt NJ, Ackerman U, Tochon-Danguy HJ, Donnan GA, Howells DW. Characterization of fluoromisonidazole binding in stroke. *Stroke*. 2006; 37(7):1862–7. <https://doi.org/10.1161/01.STR.0000226908.93295.9d> PMID: 16763190.
8. Spratt NJ, Donnan GA, Howells DW. Characterisation of the timing of binding of the hypoxia tracer FMISO after stroke. *Brain Res*. 2009; 1288:135–42. <https://doi.org/10.1016/j.brainres.2009.06.102> PMID: 19595680.
9. Spratt NJ, Donnan GA, McLeod DD, Howells DW. 'Salvaged' stroke ischaemic penumbra shows significant injury: studies with the hypoxia tracer FMISO. *J Cereb Blood Flow Metab*. 2011; 31(3):934–43. <https://doi.org/10.1038/jcbfm.2010.174> PMID: 20877386.
10. Takasawa M, Beech JS, Fryer TD, Hong YT, Hughes JL, Igase K, et al. Imaging of brain hypoxia in permanent and temporary middle cerebral artery occlusion in the rat using 18F-fluoromisonidazole and positron emission tomography: a pilot study. *J Cereb Blood Flow Metab*. 2007; 27(4):679–89. <https://doi.org/10.1038/sj.jcbfm.9600405> PMID: 17033692.
11. Takasawa M, Beech JS, Fryer TD, Jones PS, Ahmed T, Smith R, et al. Single-subject statistical mapping of acute brain hypoxia in the rat following middle cerebral artery occlusion: a microPET study. *Exp Neurol*. 2011; 229(2):251–8. <https://doi.org/10.1016/j.expneurol.2011.02.005> PMID: 21335004.
12. Rojas S, Herance JR, Abad S, Jimenez X, Pareto D, Ruiz A, et al. Evaluation of hypoxic tissue dynamics with 18F-FMISO PET in a rat model of permanent cerebral ischemia. *Mol Imaging Biol*. 2011; 13(3):558–64. <https://doi.org/10.1007/s11307-010-0371-4> PMID: 20602176.
13. Schirrmacher R, Dea M, Heiss WD, Kostikov A, Funck T, Quessy S, et al. Which Aspects of Stroke Do Animal Models Capture? A Multitracer Micro-PET Study of Focal Ischemia with Endothelin-1. *Cerebrovasc Dis*. 2016; 41(3–4):139–47. <https://doi.org/10.1159/000442997> PMID: 26752046.
14. Jensen-Kondering U, Manavaki R, Ejaz S, Sawiak SJ, Carpenter TA, Fryer TD, et al. Brain hypoxia mapping in acute stroke: Back-to-back T2\* MR versus 18F-fluoromisonidazole PET in rodents. *Int J Stroke*. 2017; 12(7):752–60. <https://doi.org/10.1177/1747493017706221> PMID: 28523963.
15. Alawneh JA, Moustafa RR, Marrapu ST, Jensen-Kondering U, Morris RS, Jones PS, et al. Diffusion and perfusion correlates of the 18F-MISO PET lesion in acute stroke: pilot study. *Eur J Nucl Med Mol Imaging*. 2014; 41(4):736–44. <https://doi.org/10.1007/s00259-013-2581-x> PMID: 24126468.
16. Markus R, Donnan GA, Kazui S, Read S, Hirano T, Scott AM, et al. Statistical parametric mapping of hypoxic tissue identified by [(18)F]fluoromisonidazole and positron emission tomography following

- acute ischemic stroke. *Neuroimage*. 2002; 16(2):425–33. <https://doi.org/10.1006/nimg.2002.1056> PMID: 12030827.
17. Markus R, Reutens DC, Kazui S, Read S, Wright P, Chambers BR, et al. Topography and temporal evolution of hypoxic viable tissue identified by 18F-fluoromisonidazole positron emission tomography in humans after ischemic stroke. *Stroke*. 2003; 34(11):2646–52. <https://doi.org/10.1161/01.STR.0000094422.74023.FF> PMID: 14563970.
18. Markus R, Reutens DC, Kazui S, Read S, Wright P, Pearce DC, et al. Hypoxic tissue in ischaemic stroke: persistence and clinical consequences of spontaneous survival. *Brain*. 2004; 127(Pt 6):1427–36. <https://doi.org/10.1093/brain/awh162> PMID: 15130953.
19. Read SJ, Hirano T, Abbott DF, Markus R, Sachinidis JI, Tochon-Danguy HJ, et al. The fate of hypoxic tissue on 18F-fluoromisonidazole positron emission tomography after ischemic stroke. *Ann Neurol*. 2000; 48(2):228–35. PMID: 10939574.
20. Read SJ, Hirano T, Abbott DF, Sachinidis JI, Tochon-Danguy HJ, Chan JG, et al. Identifying hypoxic tissue after acute ischemic stroke using PET and 18F-fluoromisonidazole. *Neurology*. 1998; 51(6):1617–21. PMID: 9855512.
21. Lee GH, Kim JS, Oh SJ, Kang DW, Kim JS, Kwon SU. (18)F-fluoromisonidazole (FMISO) Positron Emission Tomography (PET) Predicts Early Infarct Growth in Patients with Acute Ischemic Stroke. *J Neuroimaging*. 2015; 25(4):652–5. <https://doi.org/10.1111/jon.12180> PMID: 25311732.
22. Falcao AL, Reutens DC, Markus R, Koga M, Read SJ, Tochon-Danguy H, et al. The resistance to ischemia of white and gray matter after stroke. *Ann Neurol*. 2004; 56(5):695–701. <https://doi.org/10.1002/ana.20265> PMID: 15505775.
23. Hirano T, Read SJ, Abbott DF, Sachinidis JI, Tochon-Danguy HJ, Egan GF, et al. No evidence of hypoxic tissue on 18F-fluoromisonidazole PET after intracerebral hemorrhage. *Neurology*. 1999; 53(9):2179–82. PMID: 10599802.
24. Sarrafzadeh AS, Nagel A, Czabanka M, Denecke T, Vajkoczy P, Plotkin M. Imaging of hypoxic-ischemic penumbra with (18)F-fluoromisonidazole PET/CT and measurement of related cerebral metabolism in aneurysmal subarachnoid hemorrhage. *J Cereb Blood Flow Metab*. 2010; 30(1):36–45. <https://doi.org/10.1038/jcbfm.2009.199> PMID: 19773799.
25. Piert M, Machulla HJ, Becker G, Aldinger P, Winter E, Bares R. Dependency of the [18F]fluoromisonidazole uptake on oxygen delivery and tissue oxygenation in the porcine liver. *Nucl Med Biol*. 2000; 27(8):693–700. PMID: 11150699.
26. Bartlett RM, Beattie BJ, Naryanan M, Georgi JC, Chen Q, Carlin SD, et al. Image-guided PO2 probe measurements correlated with parametric images derived from 18F-fluoromisonidazole small-animal PET data in rats. *J Nucl Med*. 2012; 53(10):1608–15. <https://doi.org/10.2967/jnumed.112.103523> PMID: 22933821.
27. Di Rocco RJ, Kuczyński BL, Pirro JP, Bauer A, Linder KE, Ramalingam K, et al. Imaging ischemic tissue at risk of infarction during stroke. *J Cereb Blood Flow Metab*. 1993; 13(5):755–62. <https://doi.org/10.1038/jcbfm.1993.96> PMID: 8360282.
28. Hoffman JM, Rasey JS, Spence AM, Shaw DW, Krohn KA. Binding of the hypoxia tracer [3H]misonidazole in cerebral ischemia. *Stroke*. 1987; 18(1):168–76. PMID: 3810750.
29. Singhal AB. A review of oxygen therapy in ischemic stroke. *Neurol Res*. 2007; 29(2):173–83. <https://doi.org/10.1179/016164107X181815> PMID: 17439702.
30. Poli S, Veltkamp R. Oxygen therapy in acute ischemic stroke—experimental efficacy and molecular mechanisms. *Curr Mol Med*. 2009; 9(2):227–41. PMID: 19275631.
31. Ejaz S, Emmrich JV, Sitnikov SL, Hong YT, Sawiak SJ, Fryer TD, et al. Normobaric hyperoxia markedly reduces brain damage and sensorimotor deficits following brief focal ischaemia. *Brain*. 2016; 139(Pt 3):751–64. <https://doi.org/10.1093/brain/awv391> PMID: 26767570.
32. Hong YT, Beech JS, Smith R, Baron JC, Fryer TD. Parametric mapping of [18F]fluoromisonidazole positron emission tomography using basis functions. *J Cereb Blood Flow Metab*. 2011; 31(2):648–57. <https://doi.org/10.1038/jcbfm.2010.141> PMID: 20736963.
33. Letourneur A, Freret T, Roussel S, Boulouard M, Divoux D, Toutain J, et al. Maternal hypertension during pregnancy modifies the response of the immature brain to hypoxia-ischemia: sequential MRI and behavioral investigations. *Exp Neurol*. 2012; 233(1):264–72. <https://doi.org/10.1016/j.expneurol.2011.10.014> PMID: 22051176.
34. McCabe C, Gallagher L, Gsell W, Graham D, Dominiczak AF, Macrae IM. Differences in the evolution of the ischemic penumbra in stroke-prone spontaneously hypertensive and Wistar-Kyoto rats. *Stroke*. 2009; 40(12):3864–8. <https://doi.org/10.1161/STROKEAHA.109.559021> PMID: 19797186.
35. Reid E, Graham D, Lopez-Gonzalez MR, Holmes WM, Macrae IM, McCabe C. Penumbra detection using PWI/DWI mismatch MRI in a rat stroke model with and without comorbidity: comparison of

- methods. *J Cereb Blood Flow Metab.* 2012; 32(9):1765–77. <https://doi.org/10.1038/jcbfm.2012.69> PMID: 22669479.
36. Duverger D, Mackenzie ET. The Quantification of Cerebral Infarction Following Focal Ischemia in the Rat—Influence of Strain, Arterial-Pressure, Blood-Glucose Concentration, and Age. *J Cereb Blood Flow Metab.* 1988; 8(4):449–61. <https://doi.org/10.1038/jcbfm.1988.86> PMID: 2968987.
37. Gratton JA, Sauter A, Rudin M, Lees KR, McColl J, Reid JL, et al. Susceptibility to cerebral infarction in the stroke-prone spontaneously hypertensive rat is inherited as a dominant trait. *Stroke.* 1998; 29(3):690–4. PMID: 9506614.
38. Coyle P. Different susceptibilities to cerebral infarction in spontaneously hypertensive (SHR) and normotensive Sprague-Dawley rats. *Stroke.* 1986; 17(3):520–5. PMID: 3715954.
39. Barone FC, Price WJ, White RF, Willette RN, Feuerstein GZ. Genetic hypertension and increased susceptibility to cerebral ischemia. *Neurosci Biobehav Rev.* 1992; 16(2):219–33. PMID: 1630732.
40. Brint S, Jacewicz M, Kiessling M, Tanabe J, Pulsinelli W. Focal brain ischemia in the rat: methods for reproducible neocortical infarction using tandem occlusion of the distal middle cerebral and ipsilateral common carotid arteries. *J Cereb Blood Flow Metab.* 1988; 8(4):474–85. <https://doi.org/10.1038/jcbfm.1988.88> PMID: 3392112.
41. Iadecola C, Davisson RL. Hypertension and cerebrovascular dysfunction. *Cell Metab.* 2008; 7(6):476–84. <https://doi.org/10.1016/j.cmet.2008.03.010> PMID: 18522829.
42. Amenta F, Tayebati SK, Tomassoni D. Spontaneously hypertensive rat neuroanatomy: applications to pharmacological research. *Ital J Anat Embryol.* 2010; 115(1–2):13–7. PMID: 21072984.
43. Leoni RF, Paiva FF, Henning EC, Nascimento GC, Tannus A, de Araujo DB, et al. Magnetic resonance imaging quantification of regional cerebral blood flow and cerebrovascular reactivity to carbon dioxide in normotensive and hypertensive rats. *Neuroimage.* 2011; 58(1):75–81. <https://doi.org/10.1016/j.neuroimage.2011.06.030> PMID: 21708273.
44. Coyle P, Heistad DD. Development of collaterals in the cerebral circulation. *Blood Vessels.* 1991; 28(1–3):183–9. PMID: 2001469.
45. Chan SL, Sweet JG, Bishop N, Cipolla MJ. Pial Collateral Reactivity During Hypertension and Aging: Understanding the Function of Collaterals for Stroke Therapy. *Stroke.* 2016; 47(6):1618–25. <https://doi.org/10.1161/STROKEAHA.116.013392> PMID: 27103017.
46. Shin HK, Dunn AK, Jones PB, Boas DA, Lo EH, Moskowitz MA, et al. Normobaric hyperoxia improves cerebral blood flow and oxygenation, and inhibits peri-infarct depolarizations in experimental focal ischaemia. *Brain.* 2007; 130(Pt 6):1631–42. <https://doi.org/10.1093/brain/awm071> PMID: 17468117.
47. Ejaz S, Williamson DJ, Ahmed T, Sitnikov S, Hong YT, Sawiak SJ, et al. Characterizing infarction and selective neuronal loss following temporary focal cerebral ischemia in the rat: a multi-modality imaging study. *Neurobiol Dis.* 2013; 51:120–32. <https://doi.org/10.1016/j.nbd.2012.11.002> PMID: 23146994.
48. Hughes JL, Beech JS, Jones PS, Wang D, Menon DK, Baron JC. Mapping selective neuronal loss and microglial activation in the salvaged neocortical penumbra in the rat. *Neuroimage.* 2010; 49(1):19–31. <https://doi.org/10.1016/j.neuroimage.2009.08.047> PMID: 19716426.
49. Buchan AM, Xue D, Slivka A. A new model of temporary focal neocortical ischemia in the rat. *Stroke.* 1992; 23(2):273–9. PMID: 1561658.
50. Ejaz S, Emmrich JV, Sawiak SJ, Williamson DJ, Baron JC. Cortical selective neuronal loss, impaired behavior, and normal magnetic resonance imaging in a new rat model of true transient ischemic attacks. *Stroke.* 2015; 46(4):1084–92. <https://doi.org/10.1161/STROKEAHA.114.007581> PMID: 25669312.
51. Kinahan PE, Rogers JG. Analytic 3D imaging reconstruction using all detected events. *IEEE Trans Nucl Sci.* 1989; 36:964–8.
52. Dijkhuizen RM, Ren J, Mandeville JB, Wu O, Ozdag FM, Moskowitz MA, et al. Functional magnetic resonance imaging of reorganization in rat brain after stroke. *Proc Natl Acad Sci U S A.* 2001; 98(22):12766–71. <https://doi.org/10.1073/pnas.231235598> PMID: 11606760.
53. von Bornstadt D, Houben T, Seidel JL, Zheng Y, Dilekoz E, Qin T, et al. Supply-demand mismatch transients in susceptible peri-infarct hot zones explain the origins of spreading injury depolarizations. *Neuron.* 2015; 85(5):1117–31. <https://doi.org/10.1016/j.neuron.2015.02.007> PMID: 25741731.
54. Paxinos G, Watson C. *The Rat Brain in Stereotaxic Coordinates.* Third ed. San Diego/London: Academic Press; 1996.
55. Anderson TW, Darling D.A. A Test of Goodness-of-Fit. *J Am Stat Assoc.* 1954; 49:765–9.
56. Williamson DJ, Ejaz S, Sitnikov S, Fryer TD, Sawiak SJ, Burke P, et al. A comparison of four PET tracers for brain hypoxia mapping in a rodent model of stroke. *Nucl Med Biol.* 2013; 40(3):338–44. <https://doi.org/10.1016/j.nucmedbio.2012.11.012> PMID: 23294900.



57. Piert M, Machulla H, Becker G, Stahlschmidt A, Patt M, Aldinger P, et al. Introducing fluorine-18 fluoromisonidazole positron emission tomography for the localisation and quantification of pig liver hypoxia. *Eur J Nucl Med.* 1999; 26(2):95–109. PMID: [9933343](#).
58. Baskerville TA, Deuchar GA, McCabe C, Robertson CA, Holmes WM, Santosh C, et al. Influence of 100% and 40% oxygen on penumbral blood flow, oxygen level, and T2\*-weighted MRI in a rat stroke model. *J Cereb Blood Flow Metab.* 2011; 31(8):1799–806. <https://doi.org/10.1038/jcbfm.2011.65> PMID: [21559031](#).
59. Liu S, Liu W, Ding W, Miyake M, Rosenberg GA, Liu KJ. Electron paramagnetic resonance-guided normobaric hyperoxia treatment protects the brain by maintaining penumbral oxygenation in a rat model of transient focal cerebral ischemia. *J Cereb Blood Flow Metab.* 2006; 26(10):1274–84. <https://doi.org/10.1038/sj.jcbfm.9600277> PMID: [16421507](#).
60. Liu S, Shi H, Liu W, Furuichi T, Timmins GS, Liu KJ. Interstitial pO<sub>2</sub> in ischemic penumbra and core are differentially affected following transient focal cerebral ischemia in rats. *J Cereb Blood Flow Metab.* 2004; 24(3):343–9. <https://doi.org/10.1097/01.WCB.0000110047.43905.01> PMID: [15091115](#).
61. Hughes JL, Jones PS, Beech JS, Wang D, Menon DK, Aigbirhio FI, et al. A microPET study of the regional distribution of [<sup>11</sup>C]-PK11195 binding following temporary focal cerebral ischemia in the rat. Correlation with post mortem mapping of microglia activation. *Neuroimage.* 2012; 59(3):2007–16. <https://doi.org/10.1016/j.neuroimage.2011.10.060> PMID: [22056528](#).
62. Kang BT, Leoni RF, Silva AC. Impaired CBF regulation and high CBF threshold contribute to the increased sensitivity of spontaneously hypertensive rats to cerebral ischemia. *Neuroscience.* 2014; 269:223–31. <https://doi.org/10.1016/j.neuroscience.2014.03.031> PMID: [24680939](#).
63. Rewell SS, Jeffreys AL, Sastra SA, Cox SF, Fernandez JA, Aleksoska E, et al. Hypothermia revisited: Impact of ischaemic duration and between experiment variability. *J Cereb Blood Flow Metab.* 2017; 37(10):3380–90. <https://doi.org/10.1177/0271678X16688704> PMID: [28084873](#).
64. Hom S, Fleegal MA, Egleton RD, Campos CR, Hawkins BT, Davis TP. Comparative changes in the blood-brain barrier and cerebral infarction of SHR and WKY rats. *Am J Physiol Regul Integr Comp Physiol.* 2007; 292(5):R1881–92. <https://doi.org/10.1152/ajpregu.00761.2005> PMID: [17234953](#).
65. Ejaz S, Williamson DJ, Jensen-Kondering U, Ahmed T, Sawiak SJ, Baron JC. What is the Optimal Duration of Middle-Cerebral Artery Occlusion Consistently Resulting in Isolated Cortical Selective Neuronal Loss in the Spontaneously Hypertensive Rat? *Front Neurol.* 2015; 6:64. <https://doi.org/10.3389/fneur.2015.00064> PMID: [25859239](#).
66. Brown AT, Arthur MC, Nix JS, Montgomery JA, Skinner RD, Roberson PK, et al. Dodecafluoropentane Emulsion (DDFPe) Decreases Stroke Size and Improves Neurological Scores in a Permanent Occlusion Rat Stroke Model. *Open Neurol J.* 2014; 8:27–33. <https://doi.org/10.2174/1874205X01408010027> PMID: [25674164](#).
67. Sun L, Marti HH, Veltkamp R. Hyperbaric oxygen reduces tissue hypoxia and hypoxia-inducible factor-1 alpha expression in focal cerebral ischemia. *Stroke.* 2008; 39(3):1000–6. <https://doi.org/10.1161/STROKEAHA.107.490599> PMID: [18239183](#).
68. Seiffge DJ, Lapina NE, Tsagogiorgas C, Theisinger B, Henning RH, Schilling L. Improvement of oxygen supply by an artificial carrier in combination with normobaric oxygenation decreases the volume of tissue hypoxia and tissue damage from transient focal cerebral ischemia. *Exp Neurol.* 2012; 237(1):18–25. <https://doi.org/10.1016/j.expneurol.2012.06.007> PMID: [22728375](#).
69. Baskin A, Buchegger F, Seimille Y, Ratib O, Garibotto V. PET Molecular Imaging of Hypoxia in Ischemic Stroke: An Update. *Curr Vasc Pharmacol.* 2015; 13(2):209–17. PMID: [24188484](#).
70. Werner P, Saur D, Zeisig V, Ettrich B, Patt M, Sattler B, et al. Simultaneous PET/MRI in stroke: a case series. *J Cereb Blood Flow Metab.* 2015; 35(9):1421–5. <https://doi.org/10.1038/jcbfm.2015.158> PMID: [26174332](#).
71. Beynon C, Sun L, Marti HH, Heiland S, Veltkamp R. Delayed hyperbaric oxygenation is more effective than early prolonged normobaric hyperoxia in experimental focal cerebral ischemia. *Neurosci Lett.* 2007; 425(3):141–5. <https://doi.org/10.1016/j.neulet.2007.07.009> PMID: [17850964](#).
72. Henninger N, Bratane BT, Bastan B, Bouley J, Fisher M. Normobaric hyperoxia and delayed tPA treatment in a rat embolic stroke model. *J Cereb Blood Flow Metab.* 2009; 29(1):119–29. <https://doi.org/10.1038/jcbfm.2008.104> PMID: [18766195](#).
73. Hou H, Grinberg O, Williams B, Grinberg S, Yu H, Alvarenga DL, et al. The effect of oxygen therapy on brain damage and cerebral pO<sub>2</sub> in transient focal cerebral ischemia in the rat. *Physiol Meas.* 2007; 28(8):963–76. <https://doi.org/10.1088/0967-3334/28/8/017> PMID: [17664686](#).
74. Singhal AB, Dijkhuizen RM, Rosen BR, Lo EH. Normobaric hyperoxia reduces MRI diffusion abnormalities and infarct size in experimental stroke. *Neurology.* 2002; 58(6):945–52. PMID: [11914413](#).
75. Liang J, Qi Z, Liu W, Wang P, Shi W, Dong W, et al. Normobaric hyperoxia slows blood-brain barrier damage and expands the therapeutic time window for tissue-type plasminogen activator treatment in



- cerebral ischemia. *Stroke*. 2015; 46(5):1344–51. <https://doi.org/10.1161/STROKEAHA.114.008599> PMID: 25804925.
76. Fujiwara N, Murata Y, Arai K, Egi Y, Lu J, Wu O, et al. Combination therapy with normobaric oxygen (NBO) plus thrombolysis in experimental ischemic stroke. *BMC Neurosci*. 2009; 10:79. <https://doi.org/10.1186/1471-2202-10-79> PMID: 19604385.
77. Esposito E, Mandeville ET, Hayakawa K, Singhal AB, Lo EH. Effects of normobaric oxygen on the progression of focal cerebral ischemia in rats. *Exp Neurol*. 2013; 249:33–8. <https://doi.org/10.1016/j.expneurol.2013.08.005> PMID: 23958492.
78. Flynn EP, Auer RN. Eubarc hyperoxemia and experimental cerebral infarction. *Ann Neurol*. 2002; 52(5):566–72. <https://doi.org/10.1002/ana.10322> PMID: 12402253.
79. Jin X, Liu J, Liu KJ, Rosenberg GA, Yang Y, Liu W. Normobaric hyperoxia combined with minocycline provides greater neuroprotection than either alone in transient focal cerebral ischemia. *Exp Neurol*. 2013; 240:9–16. <https://doi.org/10.1016/j.expneurol.2012.11.018> PMID: 23195595.
80. Kim HY, Singhal AB, Lo EH. Normobaric hyperoxia extends the reperfusion window in focal cerebral ischemia. *Ann Neurol*. 2005; 57(4):571–5. <https://doi.org/10.1002/ana.20430> PMID: 15786465.
81. Miyamoto O, Auer RN. Hypoxia, hyperoxia, ischemia, and brain necrosis. *Neurology*. 2000; 54(2):362–71. PMID: 10668697.
82. Liu C, Weaver J, Liu KJ. Rapid conditioning with oxygen oscillation: neuroprotection by intermittent normobaric hyperoxia after transient focal cerebral ischemia in rats. *Stroke*. 2012; 43(1):220–6. <https://doi.org/10.1161/STROKEAHA.111.625756> PMID: 22020028.
83. Shin HK, Oka F, Kim JH, Atochin D, Huang PL, Ayata C. Endothelial dysfunction abrogates the efficacy of normobaric hyperoxia in stroke. *J Neurosci*. 2014; 34(46):15200–7. <https://doi.org/10.1523/JNEUROSCI.1110-14.2014> PMID: 25392489.
84. Henninger N, Bouley J, Nelligan JM, Sicard KM, Fisher M. Normobaric hyperoxia delays perfusion/diffusion mismatch evolution, reduces infarct volume, and differentially affects neuronal cell death pathways after suture middle cerebral artery occlusion in rats. *J Cereb Blood Flow Metab*. 2007; 27(9):1632–42. <https://doi.org/10.1038/sj.jcbfm.9600463> PMID: 17311078.
85. Singhal AB, Benner T, Roccatagliata L, Koroshetz WJ, Schaefer PW, Lo EH, et al. A pilot study of normobaric oxygen therapy in acute ischemic stroke. *Stroke*. 2005; 36(4):797–802. <https://doi.org/10.1161/01.STR.0000158914.66827.2e> PMID: 15761201.
86. Jones TH, Morawetz RB, Crowell RM, Marcoux FW, FitzGibbon SJ, DeGirolami U, et al. Thresholds of focal cerebral ischemia in awake monkeys. *J Neurosurg*. 1981; 54(6):773–82. <https://doi.org/10.3171/jns.1981.54.6.0773> PMID: 7241187.
87. Crockard HA, Symon L, Branston NM, Juhasz J. Changes in regional cortical tissue oxygen tension and cerebral blood flow during temporary middle cerebral artery occlusion in baboons. *J Neurol Sci*. 1976; 27(1):29–44. PMID: 1249580.
88. Harris RJ, Richards PG, Symon L, Habib AH, Rosenstein J. pH, K<sup>+</sup>, and PO<sub>2</sub> of the extracellular space during ischaemia of primate cerebral cortex. *J Cereb Blood Flow Metab*. 1987; 7(5):599–604. <https://doi.org/10.1038/jcbfm.1987.111> PMID: 3654800.
89. Dohmen C, Bosche B, Graf R, Staub F, Kracht L, Sobesky J, et al. Prediction of malignant course in MCA infarction by PET and microdialysis. *Stroke*. 2003; 34(9):2152–8. <https://doi.org/10.1161/01.STR.0000083624.74929.32> PMID: 12881606.
90. Hoffman WE, Charbel FT, Edelman G, Ausman JI. Brain tissue oxygen pressure, carbon dioxide pressure, and pH during hypothermic circulatory arrest. *Surg Neurol*. 1996; 46(1):75–9. PMID: 8677493.
91. Hoffman WE, Charbel FT, Gonzalez-Portillo G, Ausman JI. Measurement of ischemia by changes in tissue oxygen, carbon dioxide, and pH. *Surg Neurol*. 1999; 51(6):654–8. PMID: 10369235.
92. Weaver J, Jalal FY, Yang Y, Thompson J, Rosenberg GA, Liu KJ. Tissue oxygen is reduced in white matter of spontaneously hypertensive-stroke prone rats: a longitudinal study with electron paramagnetic resonance. *J Cereb Blood Flow Metab*. 2014; 34(5):890–6. <https://doi.org/10.1038/jcbfm.2014.35> PMID: 24549186.
93. Mies G, Hermann D, Ganten U, Hossmann KA. Hemodynamics and metabolism in stroke-prone spontaneously hypertensive rats before manifestation of brain infarcts. *J Cereb Blood Flow Metab*. 1999; 19(11):1238–46. <https://doi.org/10.1097/00004647-199911000-00008> PMID: 10566970.
94. Henninger N, Lin E, Haussen DC, Lehman LL, Takhtani D, Selim M, et al. Leukoaraiosis and sex predict the hyperacute ischemic core volume. *Stroke*. 2013; 44(1):61–7. <https://doi.org/10.1161/STROKEAHA.112.679084> PMID: 23233384.